主页 > 医药生命 >

【medical-news】迷走神经刺激或许能缓解难治性快

Vagus Nerve Stimulation May Treat Refractory Rapid-Cycling Bipolar Disorder

NEW YORK (Reuters Health) Mar 24 - Results of a small open-label study indicate that vagus nerve stimulation (VNS) may be an effective and well-tolerated option in patients with treatment-resistant rapid-cycling bipolar disorder.

Patients with rapid-cycling bipolar disorder were excluded from a pivotal trial that led to the U.S. Food and Drug Administration's approval of VNS for major depressive episodes, Dr. Lauren B. Marangell and colleagues note in the Journal of Clinical Psychiatry for February.

"Given the unmet need for effective rapid-cycling bipolar disorder therapies, an innovative treatment may have a substantial public health impact," they also point out.

Against this backdrop, Dr. Marangell of Eli Lilly and Company, Indianapolis, Indiana and colleagues conducted a 1-year open-label pilot study of VNS in nine patients with treatment-resistant rapid-cycling bipolar disorder, which they defined as four or more fully syndromic mood disturbances in the preceding 12 months.

VNS was associated with a 38.1% (p = 0.012) mean improvement from baseline in total illness scores. "Similarly, a 37.9% improvement was exhibited in depression symptom scores, and a 40.2% improvement in mania symptom scores," the researchers report.

Specifically, VNS was associated with statistically significant reductions in symptoms as measured by the Hamilton Rating Scale for Depression (p = 0.043), the Montgomery-Asberg Depression Rating Scale (p = 0.003), the Clinical Global Assessment of Functioning scale (p = 0.013), and the Global Assessment of Functioning scale (p < 0.001).

VNS was well tolerated, "with the overall pattern of side effects during the trial being similar to those reported in the studies of epilepsy and depression," Dr. Marangell and colleagues report. The most common adverse events in the current study were voice alteration during stimulation and hoarseness. No patient discontinued VNS due to side effects.

This study suggests that VNS may be a viable option in patients with treatment-resistant rapid-cycling bipolar disorder, the team concludes. However, randomized, sham-controlled trials are needed to verify the findings.

J Clin Psychiatry 2008;69:183-189.

http://www.medscape.com/viewarticle/571874 Vagus Nerve Stimulation May Treat Refractory Rapid-Cycling Bipolar Disorder

迷走神经刺激可以治疗难治性快速循环双相情感障碍

NEW YORK (Reuters Health) Mar 24 - Results of a small open-label study indicate that vagus nerve stimulation (VNS) may be an effective and well-tolerated option in patients with treatment-resistant rapid-cycling bipolar disorder.

纽约(路透社生) 3月24日-一个小型的开放式研究表明,迷走神经刺激术(完)可能是一种有效和耐受性良好,在选择患者治疗难治性快速循环双相情感障碍。

Patients with rapid-cycling bipolar disorder were excluded from a pivotal trial that led to the U.S. Food and Drug Administration's approval of VNS for major depressive episodes, Dr. Lauren B. Marangell and colleagues note in the Journal of Clinical Psychiatry for February.

患者快速循环双相情感障碍被排除在关键的审讯导致了美国食品和药物管理局的批准,迷走神经刺激为主要抑郁症,医生劳伦乙marangell和他的同事注意到,在最近出版的临床精神科明年2月份进行。

"Given the unmet need for effective rapid-cycling bipolar disorder therapies, an innovative treatment may have a substantial public health impact," they also point out.

"由于未得到满足的需求,为有效的快速循环双相情感障碍的治疗,这是一项创新的治疗可能拥有一个庞大的公共健康影响" ,他们亦指出。

Against this backdrop, Dr. Marangell of Eli Lilly and Company, Indianapolis, Indiana and colleagues conducted a 1-year open-label pilot study of VNS in nine patients with treatment-resistant rapid-cycling bipolar disorder, which they defined as four or more fully syndromic mood disturbances in the preceding 12 months.

在此背景下,博士marangell的礼来公司,印第安纳波利斯,印第安纳和他的同事进行了一项1年期开放标签试验研究迷走神经刺激,在9例难治性快速循环双相情感障碍,而他们界定为4个或更多充分症候群的情绪干扰,在此之前的12个月。

VNS was associated with a 38.1% (p = 0.012) mean improvement from baseline in total illness scores. "Similarly, a 37.9% improvement was exhibited in depression symptom scores, and a 40.2% improvement in mania symptom scores," the researchers report.

迷走神经刺激是与38.1 % ( P值为0.012 ) ,平均改善,从基线共患病分数。 "同样, 37.9 %的改善,是展示在抑郁症状评分, 40.2 %的改善躁狂症状评分, "研究报告。

阅读本文的人还阅读:

【科普】一些食物可以缓

作者:admin@医学,生命科学    2010-11-22 05:11
医学,生命科学网